LABScreen™ PRA is a flow cytometry-based diagnostic test for screening and identifying panel-reactive antibodies in transplant patients. It utilizes advanced flow analysis technology to detect HLA antibodies, enabling precise specificity assignments critical for transplant compatibility assessment a...
Manufactured by
Thermo Fisher Scientific Inc.
China
Thermo Fisher Scientific is a world leader in scientific services with annual sales exceeding $30 billion. The company serves life sciences research, analytical challenges, medical diagnostics, and laboratory productivity through brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon, with over 80,000 employees globally.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
BUHLMANN Diagnostics
United States · 2 relevant products
iPASY Technologies Kft
Hungary · 2 relevant products
HOB Biotech Group Corp., Ltd.
China · 1 relevant product
37 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →15 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 56 closest product alternatives
BUHLMANN Diagnostics · United States
A cellular allergy diagnostic test using flow cytometry technology. Measures basophil activation to allergen stimulation for allergy assessment.
iPASY Technologies Kft · Hungary
Non-invasive urine-based diagnostic test for prostate cancer screening that analyzes PSA N-glycomic alterations using recombinant antibody technology. Reduces false positives, requires no specialized operator training, and provides risk stratification for clinical decision-making. Designed for cost-effective accessibility in resource-limited settings.
iPASY Technologies Kft · Hungary
Diagnostic assay utilizing recombinant antibody technology to evaluate prostate cancer risk and aggressiveness from non-invasive urine samples. Designed for simplicity of operation and cost-effective accessibility in resource-limited settings.
53 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products